浙江交科(002061.SZ):下属公司浙江交工预中标235国道泰顺司前至罗阳段改建工程施工第SG01标段项目
格隆汇5月27日丨浙江交科(002061.SZ)公布,近日,公司收到下属公司浙江交工集团股份有限公司(“浙江交工”)发来的通知,浙江交工参与235国道泰顺司前至罗阳段改建工程施工第SG01标段施工投标,2020年5月23日,招标人公示了评标结果,浙江交工为中标候选人。
项目名称:235国道泰顺司前至罗阳段改建工程施工第SG01标段;拟中标金额:人民币约5.85亿元;工期:1095日历天。
拟中标项目符合公司主营业务战略布局,能够巩固公司在长三角地区市场竞争力和市场占有率,若上述中标项目顺利实施将对公司业绩将产生积极影响。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.